Unusual fatigue, frequent infections, easy bruising, or abnormal blood work are often what first bring a patient to a hematologist, and the diagnosis that follows, acute or chronic, myeloid or lymphocytic, changes the entire treatment plan. Chronic myeloid leukemia, for instance, is driven by the Philadelphia chromosome in nearly all cases and now responds well to daily targeted pills called tyrosine kinase inhibitors, while acute leukemias are typically treated with chemotherapy, sometimes combined with immunotherapy or, for relapsed cases, CAR-T cell therapy.
When high-risk disease or relapse requires it, a bone marrow transplant replaces the damaged blood-forming cells, though it isn't needed for every patient: many with CML or lower-risk ALL respond well to targeted therapy alone. In Turkey, hematology centers combine molecular diagnostics with this full range of treatments, and Turquie Santé coordinates access to these specialists and the ongoing monitoring leukemia care requires, from the initial workup through treatment and follow-up.
